Alan R Crossman
Overview
Explore the profile of Alan R Crossman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
837
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fridjonsdottir E, Shariatgorji R, Nilsson A, Vallianatou T, Odell L, Schembri L, et al.
Sci Adv
. 2021 Feb;
7(2).
PMID: 33523980
l-DOPA treatment for Parkinson's disease frequently leads to dyskinesias, the pathophysiology of which is poorly understood. We used MALDI-MSI to map the distribution of l-DOPA and monoaminergic pathways in brains...
2.
Bezard E, Li Q, Hulme H, Fridjonsdottir E, Nilsson A, Pioli E, et al.
J Neurosci
. 2020 Jul;
40(35):6812-6819.
PMID: 32690616
Parkinson's disease (PD) is characterized by severe locomotor deficits and is commonly treated with the dopamine precursor L-DOPA, but its prolonged usage causes dyskinesias referred to as L-DOPA-induced dyskinesia (LID)....
3.
Cenci M, Crossman A
Mov Disord
. 2018 Mar;
33(6):889-899.
PMID: 29488257
Understanding the biological mechanisms of l-dopa-induced motor complications is dependent on our ability to investigate these phenomena in animal models of Parkinson's disease. The most common motor complications consist in...
4.
5.
Bastide M, Meissner W, Picconi B, Fasano S, Fernagut P, Feyder M, et al.
Prog Neurobiol
. 2015 Jul;
132:96-168.
PMID: 26209473
Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately experienced by the vast majority of patients. In addition,...
6.
Shariatgorji M, Nilsson A, Goodwin R, Kallback P, Schintu N, Zhang X, et al.
Neuron
. 2014 Dec;
84(4):697-707.
PMID: 25453841
Current neuroimaging techniques have very limited abilities to directly identify and quantify neurotransmitters from brain sections. We have developed a molecular-specific approach for the simultaneous imaging and quantitation of multiple...
7.
Ko W, Martin-Negrier M, Bezard E, Crossman A, Ravenscroft P
Neurobiol Dis
. 2014 Jun;
70:138-48.
PMID: 24969021
Regulators of G-protein signalling (RGS) proteins are implicated in striatal G-protein coupled receptor (GPCR) sensitisation in the pathophysiology of l-DOPA-induced abnormal involuntary movements (AIMs), also known as dyskinesia (LID), in...
8.
Kobylecki C, Burn D, Kass-Iliyya L, Kellett M, Crossman A, Silverdale M
Parkinsonism Relat Disord
. 2014 Feb;
20(4):452-5.
PMID: 24521874
Background: The antiepileptic drug topiramate reduces levodopa-induced dyskinesia without exacerbating parkinsonism in animal models. We report a randomized, double-blind, placebo-controlled crossover trial in patients with Parkinson's disease and levodopa-induced dyskinesia....
9.
Bourdenx M, Nilsson A, Wadensten H, Falth M, Li Q, Crossman A, et al.
Neurobiol Dis
. 2013 Oct;
62:307-12.
PMID: 24148855
A role for enhanced peptidergic transmission, either opioidergic or not, has been proposed for the generation of l-3,4-dihydroxyphenylalanine (l-DOPA)-induced dyskinesia (LID) on the basis of in situ hybridization studies showing...
10.
Kobylecki C, Crossman A, Ravenscroft P
Exp Neurol
. 2013 Jan;
247:476-84.
PMID: 23360800
Abnormal corticostriatal plasticity is a key mechanism of L-DOPA-induced dyskinesia (LID) in Parkinson's disease (PD). Antagonists at glutamatergic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, such as IEM 1460, reduce induction and expression...